Neoleukin Therapeutics

Neoleukin Therapeutics: Lead program NL-201: is a dual-acting IL-2 and IL-15 agonist immunotherapy for cancer, designed to improve tolerability and activity by eliminating the alpha receptor binding interface (IND completed 4Q20). First de novo protein therapeutic ever created.
Healthcare/Drug Manufacturers
Based in...
US - Pacific
Clinical Stage
Pre-Clinical Stage
Disease Space
Allergy, Autoimmune, Immuno-Oncology, Infectious Disease, Oncology
Public, USA
Market Cap
500MM - 1B
1616 Eastlake Avenue E
Suit 360
Seattle, WA 98109
United States

Company Participants at Neoleukin Investor R&D Showcase - AACR 2020 (Virtual)

  • Jonathan G. Drachman, CEO

Top 10 Holders of Neoleukin Therapeutics, Inc

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Redmile Group LLC 10.77 4,131,869 50.20 13F 12/31/20
Baker Bros. Advisors LP 9.96 3,821,740 46.43 13F 12/31/20
Ecor1 Capital LLC 8.14 3,122,704 37.94 Stakes 12/31/20
Pictet Asset Management Ltd. 5.28 2,024,560 24.60 13F 12/31/20
BlackRock Fund Advisors 4.07 1,561,383 18.97 13F 12/31/20
Boxer Capital LLC 3.91 1,501,058 18.24 13F 12/31/20
Opaleye Management, Inc. 3.61 1,386,300 16.84 13F 12/31/20
Point72 Asset Management LP (Old) 3.12 1,195,725 14.53 13F 12/31/20
The Vanguard Group, Inc. 3.08 1,180,044 14.34 Funds 2/28/21
State Street Corp. 3.07 1,177,350 14.30 13F 12/31/20
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2021 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.